TAK TAK
Company Profile ↓Company Overview
TAK (TAK) is a publicly traded company listed on with a market capitalization of $26.61B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Mar 2026 Revenue of $4.51T (-1.7% YoY); net profit $-152.39B.
- Trailing 12 Months Year-on-year growth — revenue -1.7%, earnings -241.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 3.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 3.81% |
| 1 Year: | -1.66% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -241.20% |
Stock Price Performance
| 1 Year: | +18.08% |
| 6 Months: | -4.07% |
| 3 Months: | +1.03% |
| 1 Month: | -1.42% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- Death Cross3d ago
- RSI (14)48.61 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
| Revenue | 1.11T | 1.11T | 1.19T | 1.09T | 1.22T |
| Cost of Revenue | 384.68B | 380.06B | 401.15B | 405.70B | 406.68B |
| Gross Profit | 722.01B | 732.74B | 790.55B | 688.84B | 813.22B |
| Operating Expenses | 537.45B | 663.74B | 621.73B | 646.77B | 611.81B |
| Operating Income | 184.56B | 69.00B | 168.82B | 42.07B | 201.42B |
| EBITDA | 389.43B | 316.47B | 448.13B | -456.95B | 337.49B |
| Interest Expense | 107.16B | 83.14B | 123.63B | -165.80B | 63.84B |
| Pretax Income | 150.63B | 28.17B | 133.86B | -455.02B | 162.72B |
| Tax Provision | 26.35B | 39.90B | 30.13B | -86.61B | 49.46B |
| Net Income | 124.24B | -11.80B | 103.64B | -368.47B | 113.20B |
| Diluted EPS | 39.12 | - | - | - | 35.27 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue | 4.03T | 4.26T | 4.58T | 4.51T |
| Cost of Revenue | 1.24T | 1.43T | 1.58T | 1.57T |
| Gross Profit | 2.78T | 2.84T | 3.00T | 2.93T |
| Operating Expenses | 2.20T | 2.53T | 2.53T | 2.47T |
| Operating Income | 587.81B | 309.90B | 466.37B | 464.45B |
| EBITDA | 1.16T | 900.33B | 1.07T | 726.89B |
| Interest Expense | 116.97B | 119.53B | 137.31B | 148.12B |
| Pretax Income | 375.09B | 52.79B | 175.08B | -142.35B |
| Tax Provision | 58.05B | -91.41B | 66.94B | 9.77B |
| Net Income | 317.02B | 144.07B | 107.93B | -152.39B |
| Diluted EPS | 100.97 | 45.58 | 33.62 | -48.38 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 13.96T | 15.11T | 14.25T | 15.51T |
| Current Assets | - | 2.40T | 2.56T | 2.52T | 3.09T |
| Cash & Equivalents | - | 533.53B | 457.80B | 385.11B | 595.05B |
| Inventory | - | 986.46B | 1.21T | 1.22T | 1.40T |
| Receivables | - | 674.69B | 718.67B | 770.90B | 977.36B |
| Total Liabilities | - | 7.60T | 7.83T | 7.31T | 8.08T |
| Current Liabilities | - | 2.48T | 2.31T | 2.51T | 2.83T |
| Long Term Debt | - | 4.04T | 4.48T | 3.97T | 4.37T |
| Total Debt | - | 4.38T | 4.84T | 4.52T | 4.88T |
| Total Equity | - | 6.35T | 7.27T | 6.94T | 7.43T |
| Shares Outstanding | - | 1.58B | 1.58B | 1.59B | 1.59B |
Cash Flows (Annual)
Figures in USD.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 977.16B | 716.34B | 1.06T | 1.04T |
| Investing Cash Flow | - | -607.10B | -463.86B | -367.06B | -369.14B |
| Financing Cash Flow | - | -709.15B | -354.42B | -751.42B | -496.82B |
| Capital Expenditure | - | -633.69B | -480.73B | -379.62B | -414.66B |
| Free Cash Flow | - | 343.47B | 235.61B | 677.56B | 626.77B |
| Net Change in Cash | - | -339.09B | -101.93B | -61.30B | 175.47B |
Ratios (Annual)
Figures in %.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Gross Margin % | 69.1% | 66.5% | 65.5% | 65.1% |
| Operating Margin % | 14.6% | 7.3% | 10.2% | 10.3% |
| Net Margin % | 7.9% | 3.4% | 2.4% | -3.4% |
| ROE % | 5.0% | 2.0% | 1.6% | -2.1% |
| ROCE % | 5.1% | 2.4% | 4.0% | 3.7% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TAK
Why (TAK) Price Action Is Critical for Tactical Trading - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxNYTgydE9DWUdJX1d6RVJRNC1vOEhlRVp2TGdBTUZIdWlyelpIWFdRLW10TC1QLWpwclQ1T0FIb0l2dVIzMWdmRTFmR3IzaGZ4NnduZ1lsVEZ6RW5pd2hTSW9fMGJsbVl0ZzJ2Mk9HNk5RSVpzNllsWk5GSVFUSFpwTUVSQ2FGLUd2bUl6c3…
Is Takeda Pharmaceutical Company Limited (TAK) Stock Positioned for Growth After Strong LATITUDE Atlas Study Data? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxOMnlTVE96dXFleVkwdWRIQlhkc1VHWWhjSG1qbmVhVVRjYm83NzBOaWczNHZJMm5fQjRoY21SRXc5V1BKalk1RHhocXZJU1BhdmhwVUUtVTUybDNUUFd5MzdjSjZIVVNwQ3hwQ3p5WGgyeGtBZ2Nad2laTXpVM3YxQ0s5bjhhemJlVUZwMF…
HK Stock Market Movement | Tak Cheong Holdings (00199) Rises Over 13% Again - Moomoo
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxQbEZLanVSdm9DZGFpMzFHRTdQbHdZODhnTW1RSmRoWlVxdGxrRWdieE03eEpZaFMySWprUnVkbjVyU0FkeGQ4akR4d3F3ZGx0cU10bFZfQTNRbUotUjh6NGVBZ1lwcDdGZ1dOYTh5ZWlqNGhoSWlvbXRiX3lJdi1wemdQc203R1hEZ0g2Sm…
Takeda Pharmaceutical: The Downside Was Forecastable (NYSE:TAK) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxOY3BEQzFhQ0I0dTNQTEFZVnRFXzdadzRDNlhRZ2h5cXNCNFVIbnRtVi1Ydnd4TmJHdHBOYmVTWjgwbkQtekZRRTRsRDFTVGJGR2tWbnhpdXRfanZQS0xhZGo4WmRja3l6cG0wN1B5Z3F5ZUR4YzJNYllONmE4bXBsV3hiUjJsRVpJaHc3OE…
Analysts Have Conflicting Sentiments on These Healthcare Companies: Takeda Pharmaceutical Company (TAK), Align Tech (ALGN) and Conmed (CNMD) - theglobeandmail.com
<a href="https://news.google.com/rss/articles/CBMivgJBVV95cUxOZVZIRXBCRlExUjE1dEtzT0pwY2JvcDFnRHhEQnY0QlNLLUZ3aWZjaVNwZHJ2RXAxVkJfODRaV2VXQjlOSG9mT3RDMTlxbU1QWEdpbjhCYUdVNGpONklOOTRjVi1DbUk3M3JESWg0U0tmem8wYkhyeHk1VXR2cDc0QXh2NUxNLXJRWVZKSE…
Takeda's new PID therapy cut infusion volume in half in late trial - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxOVmVBYVpvZHlpQnBfYVJsUm9RbnFSZ19XWUhxSmVteWRBMzNkV2VmSU5oZ3F6Y01ydm11RnVrc1J3UXoxYmZqZFUyZWZ3d3BrZmhJYTJXNXhubjRKVjZCR3BwN25Kbl8wQm00N2I5aHl3RGRiS09GSEtjYk15Nks0WGdQYXZqMzRlR3dOWW…
TAK — Frequently Asked Questions
What is the current share price of TAK?
As of 2026-08-05 17:25 PDT, TAK trades at $16.72 on NASDAQ/NYSE. Its 52-week range is $13.23 to $18.80.
What is the market capitalisation of TAK?
TAK has a market capitalisation of $26.61B on NASDAQ/NYSE.
What is the P/E ratio of TAK?
TAK trades at a trailing price-to-earnings (P/E) ratio of -0.35.
What is the return on equity (ROE) of TAK?
TAK has a return on equity (ROE) of -2.05%. Its return on capital employed (ROCE) is 3.66%.
Is TAK a good stock to buy?
This page provides a data-driven analysis of TAK, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.